This page compares BPC-157 and TB-500 with standard recovery methods. The ratings are editorial judgments. As of October 2026, no trial has compared them head-to-head, and a 2025 systematic review of BPC-157 found 35 preclinical studies against one clinical study. FDA reports no human exposure data for the TB-500 fragment.
| Method |
Recovery Speed |
Convenience |
Cost |
Evidence |
| BPC-157/TB-500 |
Unknown in humans |
Moderate |
High |
Preliminary (animal) |
| Sleep optimization |
Moderate |
High |
Free |
Strong |
| Nutrition timing |
Moderate |
High |
Low |
Strong |
| Cold therapy |
Moderate |
Moderate |
Low |
Moderate |
| Massage/soft tissue |
Moderate |
Low |
Moderate |
Moderate |
| Injury Type |
Best Modality |
Peptide Role |
Timeline |
| Muscle strain |
Rest + rehab |
Experimental |
2-4 weeks |
| Tendon injury |
Physical therapy |
Experimental |
4-12 weeks |
| Joint inflammation |
Multiple approaches |
Unproven |
Variable |
| General soreness |
Traditional methods |
Not studied |
24-72 hours |
| Combination |
Tested together? |
Notes |
| Peptides + sleep |
No |
Helps on its own |
| Peptides + nutrition |
No |
Matters regardless |
| Peptides + cold therapy |
No |
Timing-dependent |
| Peptides + active recovery |
No |
Reduced soreness (2018 meta-analysis) |
| Recovery Investment |
Monthly Cost |
Recovery Benefit |
Value |
| Sleep optimization |
$0-50 |
High |
Excellent |
| Nutrition focus |
$50-150 |
High |
Excellent |
| Peptide protocols (unapproved vials) |
$200-400 |
Unproven |
Uncertain |
| Professional services |
$200-500 |
Moderate |
Moderate |
| Training Phase |
Primary Methods |
Peptide Use |
| High volume |
Sleep, nutrition |
Some users add (untested) |
| Injury present |
Rehab |
Some users add (untested) |
| Deload |
Traditional |
Reduced/none |
| Competition prep |
All legal methods |
None for tested athletes |
As of October 2026, WADA bans BPC-157 (S0) and TB-500 (S2.3) at all times, a point our page on the ethics of recovery peptides takes up.
No controlled trial has tested either peptide for human recovery. As of October 2026, a placebo-controlled pilot of BPC-157 after rotator cuff repair is not yet recruiting. Our BPC-157 profile and long-term effects pages cover safety.
| Dimension |
Peptides |
SARMs |
Traditional protocols |
| Mechanism |
Pathway-specific signaling |
Androgen receptor binding |
Variable by protocol |
| Typical dose range |
Compound-specific |
Compound-specific |
Unknown |
| Common side effects |
Injection reactions |
Hormone or tissue risk |
Protocol-dependent |
| WADA status |
Prohibited (S0, S2.3) |
Prohibited (S1.2) |
Not prohibited |
| Evidence strength |
Preliminary to emerging |
medium |
Moderate to strong |
